📽️ 1, 2, 3... Action! 📽️This is PER — as told by the people who lived it. Hear from some of our attendees on what the PER experience truly means to them. Learn more about what PER has to offer by visiting hubs.li/Q04r2D6L0#gotoPER#testimonialtuesday
Surgery offers the best chance of cure in early-stage NSCLC, but many patients still relapse. Which resected patients need adjuvant chemotherapy, and which can safely forgo it?
Hear more from expert faculty in this free on-demand CME activity: bit.ly/4idZXxQ
How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2- Breast Cancer nitter.siddz.com/i/broadcasts/1yxBePXYN…
A PD-L1 result now decides whether a patient with metastatic TNBC gets pembrolizumab-based therapy or an ADC first, and both paths carry toxicities that need different monitoring.
Explore more with @stolaney1 and @Neil_Iyengar in this free CME activity: bit.ly/4yXHb4d
🔥 Who will face the fire at #CFS26? Matthew Lunning, DO, FACP will ask experts the toughest questions around BTK targeting in B-cell malignancies. Register: tinyurl.com/bd24ztwv Use code hotseat for 50% off registration! #Hematology#CLL@OncoAlert
PER wears pink 🎀 for the clinicians who show up for their patients every day, and for every patient, survivor, and family facing breast cancer alongside them.
Thank you to every care team making a difference. Awareness matters, and PER stands together. 💗
#BCAwarenessMonth
Starting a MEK inhibitor is only the first step in NF1-PN care. In this free CME activity, Dr Bota discusses what to expect following initiation of MEK inhibitors to treat neurofibromatosis type 1-associated plexiform neurofibromas.
Learn more: bit.ly/4BmNxw3
Which ADC first, and what next?
In this free CME activity, expert faculty work through TROP2- and HER2-directed ADC selection and sequencing across HER2+, HER2-low, and TNBC.
Learn more: bit.ly/4BmvENX
CAD often presents with nonspecific symptoms, so how do you catch it? Experts walk through DAT interpretation, cold agglutinin testing, and treatment selection in real-world cases.
Learn more & earn free CME: bit.ly/4hTeZdn
ADCs are changing HER2+ breast cancer care, and radiation planning has to keep up.
@LiorBraunstein, @Neil_Iyengar and Reshma Jagsi, MD, DPhil cover overlapping lung and cardiac toxicity, RT escalation vs de-escalation, and brain mets.
Earn free CME: bit.ly/4i7bP4E
PER is going global!🌎✈️
First stop: Madrid! Join us Oct. 26 for the latest HER2-mutant NSCLC insights.
Next up: Milan, Italy! Stay tuned for Summer 2027 breast & lung cancer education.
🔗Register for Madrid: bit.ly/4ingfp9
🔗Milan updates: bit.ly/4BeuQLe